抗疟疾药物的最新进展和发展报告于2023年
Palak K Vadodariya1, Shahnaz Alom2,3, Anu Sharma4
1Department of Pharmaceutical Sciences, Faculty of Health Sciences, Marwadi University, Rajkot, Gujarat, India.
Archiv der Pharmazie
|December 12, 2025
概括
新的异环化合物在对抗耐药疟疾方面表现有前途. 研究人员审查了2023年抗疟疾药物设计的进展,重点关注针对寄生虫功能的新药,以克服耐药性.
科学领域:
- 药用化学 医学化学
- 寄生虫学的寄生虫学
- 药物发现 药物发现 药物发现
背景情况:
- 疟疾仍然是一个关键的全球卫生挑战,每年导致数百万病例和死亡.
- 疟原虫和虫蚊子中药物耐药性的增加需要新的治疗策略.
- 之前的审查自2016年以来一直跟踪抗疟疾药物,强调需要持续更新.
研究的目的:
- 审查最近抗疟疾药物设计的进展,特别关注2023年报告的异环化合物.
- 总结这些新兴抗疟疾药物的化学结构,作用机制和治疗潜力.
- 引导正在进行的研究,以开发更安全,更有效的疟疾治疗方法.
主要方法:
- 关于2023年抗疟疾药物发现的科学出版物和报告的文献综述.
- 对异环化合物类别的分析,包括素衍生物和新型结构,如福,氨酸和氨酸衍生物.
- 检查目标寄生虫的功能,如血红细胞代谢,红细胞入侵和氧化应激通路.
主要成果:
- 素衍生物继续显示出高效的效果.
- 包括福,β-乳酸,库马林,英多尔,形态素,皮佩拉津,皮里米丁,皮罗尔,金纳,金,醇, thiazole 和 triazoles 在内的各种异环类正在成为强大的抗疟疾候选者.
- 结合多种作用机制的新混合分子正在开发,以对抗药物耐药性.
结论:
- 异环化合物是开发下一代抗疟疾药物的重要领域.
- 针对重要寄生虫功能和采用多动作策略是克服耐药性的关键.
- 对这些新型病原体的持续研究对于推动疟疾治疗和控制工作至关重要.
相关概念视频
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:29Malaria
Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...